Literature DB >> 23541937

Oncological outcome and prognostic factors in malignant parotid tumours.

Giuseppe Mercante1, Caterina Marchese2, Diana Giannarelli3, Raul Pellini2, Giovanni Cristalli2, Valentina Manciocco2, Paolo Ruscito2, Barbara Pichi2, Paolo Marchesi2, Giuseppe Spriano2.   

Abstract

OBJECTIVE: To evaluate the oncological outcome of malignant parotid tumours and identify the prognostic factors for survival. STUDY
DESIGN: Retrospective study.
METHODS: One hundred and forty-one patients with primary epithelial carcinoma of the parotid gland were examined. The overall survival (OS) and disease specific survival (DSS) rates were calculated. The DSS was evaluated according to different parameters.
RESULTS: The 5- and 10-year OS rates were 72.3% and 58.4%. The 5- and 10-year DSS rate was 75% and 71%, respectively. The univariate analysis showed that the pathological staging, clinical and pathological tumour and nodal status, surgical procedure and histological subtype significantly influenced the DSS (P ≤ 0.05). The 5- and 10-year loco-regional control rates were 82.1% and 78%. The multivariate analysis showed that the pathological nodal status and the pathological staging influenced the DSS. It further demonstrated that the clinical tumour status and the histological subtype were the most important preoperative prognostic factors.
CONCLUSION: The pathological nodal status, the pathological staging, the clinical tumour status and the histological subtype are the most important factors influencing survival in malignant parotid tumours.
Copyright © 2013 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Oncologic outcome; Parotid; Prognostic factor; Tumour

Mesh:

Year:  2013        PMID: 23541937     DOI: 10.1016/j.jcms.2013.02.003

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  6 in total

1.  Prognostic value of comorbidities in patients with carcinoma of the major salivary glands.

Authors:  Christoph Becker; Kilian Konrad Kenjiro Dahlem; Jens Pfeiffer
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-11-25       Impact factor: 2.503

2.  A retrospective study of parotid gland tumors at a single institution.

Authors:  Shiori Suzuki; Nobuyuki Bandoh; Takashi Goto; Akinobu Kubota; Akihiro Uemura; Michihisa Kono; Ryosuke Sato; Ryuhei Takeda; Shota Sakaue; Tomomi Yamaguchi-Isochi; Hiroshi Nishihara; Hidehiro Takei; Yasuaki Harabuchi
Journal:  Oncol Lett       Date:  2022-05-13       Impact factor: 3.111

3.  Oncological outcomes of preoperatively unexpected malignant tumors of the parotid gland.

Authors:  Hanaro Park; Sungjun Han; Sung Joon Park; Young Ho Jung; Soon-Hyun Ahn; Woo-Jin Jeong
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-30       Impact factor: 2.503

4.  Clinicopathological Behavior and Oncological Outcomes of Malignant Parotid Tumors in a Pakistani Population.

Authors:  Muhammad Faisal; Taskheer Abbas; Mohammad Adeel; Usman Khaleeq; Abdul Wahid Anwer; Kashif Malik; Raza Hussain; Arif Jamshed
Journal:  Cureus       Date:  2018-02-05

5.  Skin Dosimetry with EBT3 Radiochromic Film in Radiotherapy of Parotid Cancer.

Authors:  Mohammad Taghi Bahreyni Toossi; Mahdi Ghorbani; Farideh Khorshidi; Mohammad Mohammadi; Nastaran Mohamadian; Fateme Akbari; Mahdie Dayani
Journal:  J Biomed Phys Eng       Date:  2021-10-01

6.  Prognostic Value of the Lymphocyte-to-Monocyte Ratio in Patients with Parotid Gland Carcinoma.

Authors:  Takuya Mikoshiba; Hiroyuki Ozawa; Yoshihiro Watanabe; Mariko Sekimizu; Shin Saito; Keisuke Yoshihama; Shintaro Nakamura; Yorihisa Imanishi; Kaori Kameyama; Kaoru Ogawa
Journal:  Laryngoscope       Date:  2020-07-16       Impact factor: 3.325

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.